Mar 21 |
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
|
Mar 21 |
InflaRx reports FY results
|
Mar 21 |
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
|
Mar 19 |
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
|
Mar 6 |
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
|
Feb 22 |
InflaRx Appoints Jan Medina as Head of Investor Relations
|
Jan 25 |
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
|
Jan 25 |
InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions
|
Jan 4 |
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
|
Dec 1 |
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
|